drugset / Trial / NCT05189717

A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults

NCT05189717

Phase 1 Unknown 156 enrolled Shandong Suncadia Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the tolerance, and safety of HRS-8080 tablets monotherapy and combined with other anti-cancer therapy for metastatic or local advanced breast cancer in adults. To explore the reasonable dosage of HRS-8080 tablets for metastatic or local advanced breast cancer.

Timeline

Start
2022-02-17
Primary completion
2024-10-31
Completion
2025-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-8080 Unknown
Background Abemaciclib Small molecule
Background Dalpiciclib Small molecule
Background Everolimus Small molecule

Indications